iifl-logo-icon 1
iifl-logo-icon 1Budget 2024
iifl-logo-icon 1
Home

Caplin Point Laboratories Ltd Share Price

₹1,527.4
(1.45%)
Jul 26, 2024|03:32:36 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open₹1,506.95
  • Day's High₹1,558.1
  • 52 Wk High₹1,619.05
  • Prev. Close₹1,505.5
  • Day's Low₹1,505.5
  • 52 Wk Low ₹840
  • Turnover (lac)878.51
  • P/E40.29
  • Face Value₹2
  • Book Value₹187.3
  • EPS37.33
  • Mkt. Cap (Cr.)₹11,609.81
  • Div. Yield0.17
No Records Found

Caplin Point Laboratories Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

₹1,506.95

Prev. Close

₹1,505.5

Turnover(Lac.)

₹878.51

Day's High

₹1,558.1

Day's Low

₹1,505.5

52 Week's High

₹1,619.05

52 Week's Low

₹840

Book Value

₹187.3

Face Value

₹2

Mkt Cap (₹ Cr.)

11,609.81

P/E

40.29

EPS

37.33

Divi. Yield

0.17

Caplin Point Laboratories Ltd Corporate Action

16 May 2024

12:00 AM

Dividend

Dividend Amount: 2.5

Record Date: 31 May, 2024

arrow

9 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

8 Aug 2023

12:00 AM

BookCloser

arrow

7 Aug 2023

12:00 AM

AGM

Announcement Date: 07 Aug, 2023

arrow

Caplin Point Laboratories Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center

Demat Account

View More

Trading Account

View More

Caplin Point Laboratories Ltd SHAREHOLDING SNAPSHOT

27 Jul, 2024|06:58 AM
Jun-2024Mar-2024Dec-2023Sep-2023
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 70.56%

Foreign: 0.00%

Indian: 70.56%

Non-Promoter- 4.86%

Institutions: 4.86%

Non-Institutions: 24.57%

Custodian: 0.00%

Read More
Share Price

Caplin Point Laboratories Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

15.18

15.16

15.13

15.13

Preference Capital

0

0

0

0

Reserves

1,124.73

915.49

743.54

584.78

Net Worth

1,139.91

930.65

758.67

599.91

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

482.67

527.82

426.57

341.54

yoy growth (%)

-8.55

23.73

24.89

47.67

Raw materials

-194.83

-238.17

-180.11

-161.93

As % of sales

40.36

45.12

42.22

47.41

Employee costs

-26.59

-24.99

-38.82

-30.58

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

209.93

253.12

146.05

92.57

Depreciation

-22.44

-19.65

-18.98

-13.25

Tax paid

-53.71

-55.48

-43.74

-22.26

Working capital

168.2

177.62

44.02

40.41

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

-8.55

23.73

24.89

47.67

Op profit growth

3.34

45.98

51.72

49.97

EBIT growth

-17.05

73.36

57.61

58.5

Net profit growth

-20.95

93.17

45.49

55.13

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

1,694.1

1,466.73

1,269.41

1,061.29

863.2

Excise Duty

0

0

0

0

0

Net Sales

1,694.1

1,466.73

1,269.41

1,061.29

863.2

Other Operating Income

0

0

0

0

0

Other Income

67.21

56.06

38.75

23.54

41.33

View Annually Results

Caplin Point Laboratories Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,665.8

130.913,99,537.26867.60.815,536.9998.75

Zydus Lifesciences Ltd

ZYDUSLIFE

1,205.8

35.291,21,311.571,405.20.253,172.6156.19

Cipla Ltd

CIPLA

1,500.05

32.611,21,119.621,038.40.573,444.92346.41

Divis Laboratories Ltd

DIVISLAB

4,547

76.671,20,781.575310.662,259507.93

Dr Reddys Laboratories Ltd

DRREDDY

6,853.2

26.691,14,348.411,034.80.585,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

View All Peer Comparision

MORE ABOUT Caplin Point Laboratories Ltd

Management

Register Office

Registrar Office

Chairman & Non Executive Dir.

C C Paarthipan

Independent Non Exe. Director

D Sathyanarayanan

Independent Director

C K Gariyali

Independent Non Exe. Director

Deenadayalan Singaram

Independent Non Exe. Director

R Nagendran

Non Independent Executive Director / MD

Sridhar Ganesan

Registered Office

Tel: -

Website: -

Email: -

Registrar Office

Tel: -

Website: -

Email: -

Reports by Caplin Point Laboratories Ltd

Summary

Promoted by Mr. C. C. Paarthipan, Caplin Point Laboratories Limited was incorporated on April 16th, 1990. The Company is a fully integrated Pharma Company and is presently into the business of pharmaceuticals like producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market. Its main research and development facilities are located in Tamil Nadu, India and has a manufacturing plant in Puducherry, India. It has over 4000+ products registrations across the globe with over 650+ pharmaceutical formulations & over 36 therapeutic sections.Caplin markets a wide spectrum of pharmaceutical formulations and therapeutic segments in 23 countries. In addition to LATAM and Africa, it is now serving the US, European Union and other regulated markets as well. It manufactures products one among which is for injectables approved inter-alia by EU-GMP, INVIMA, Colombia, Anvisa, Brazil and US FDA. Besides these, it has extended to regulated markets like USA (plans for Canada, Australia, China and Brazil).The company came out with a public issue in Nov.94 and expanded its production capacity by setting up a new unit to manufacture its range of products, at Pondicherry. The company has retained its SSI status even after the expansion and thus will be out of the purview of the DPCO. During 1993-94, Triwin (a partnership firm) was merged with Caplin Point. The company entered into a technical agreement with American Remedies and Concord L
Read More

Company FAQs

What is the Caplin Point Laboratories Ltd share price today?

Down Arrow

The Caplin Point Laboratories Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1527.4 today.

What is the Market Cap of Caplin Point Laboratories Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Caplin Point Laboratories Ltd is ₹11609.81 Cr. as of 26 Jul ‘24

What is the PE and PB ratio of Caplin Point Laboratories Ltd?

Down Arrow

The PE and PB ratios of Caplin Point Laboratories Ltd is 40.29 and 8.22 as of 26 Jul ‘24

What is the 52 Week High and Low of Caplin Point Laboratories Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Caplin Point Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Caplin Point Laboratories Ltd is ₹840 and ₹1619.05 as of 26 Jul ‘24

What is the CAGR of Caplin Point Laboratories Ltd?

Down Arrow

Caplin Point Laboratories Ltd's CAGR for 5 Years at 28.73%, 3 Years at 16.83%, 1 Year at 75.49%, 6 Month at 4.08%, 3 Month at 10.93% and 1 Month at 7.34%.

What is the shareholding pattern of Caplin Point Laboratories Ltd?

Down Arrow

The shareholding pattern of Caplin Point Laboratories Ltd is as follows:
Promoters - 70.56 %
Institutions - 4.87 %
Public - 24.57 %

QUICKLINKS FOR Caplin Point Laboratories Ltd

Information
Share PriceFutures PriceOption Chain
Financials
Profit & LossBalance SheetCash FlowKey Ratios
Results
Quarterly ResultHalf Yearly ResultNine Monthly ResultAnnual Result
News
Company
Marketplus
Derivativesplus
IPOplus
Mutual Fundsplus
Calculatorsplus
Nifty 50plus
Companyplus
Loansplus
Knowledge Centerplus
Newsplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Marketplus
Derivativesplus
IPOplus
Mutual Fundsplus
Calculatorsplus
Nifty 50plus
Companyplus
Loansplus
Knowledge Centerplus
Newsplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

About
IIFL Group
Products & Services
Trading Documentation
Useful Links
ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.